Current and planned trials with capecitabine in adjuvant/neoadjuvant therapy of breast cancer.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The demonstration of the activity of capecitabine (Xeloda) in advanced breast cancer and of the ability of capecitabine/docetaxel (Taxotere) to improve tumor response, time to disease progression, and survival in this setting has prompted considerable interest in examining uses of capecitabine in adjuvant and neoadjuvant therapy. Trials are planned to compare capecitabine/docetaxel with docetaxel after AC in the adjuvant and neoadjuvant settings, weekly paclitaxel vs capecitabine/docetaxel followed by fluorouracil (5-FU)/epirubicin (Ellence)/cyclophosphamide and local surgery in both adjuvant and neoadjuvant settings, and AC or cyclophosphamide/methotrexate/5-FU vs single-agent capecitabine in adjuvant therapy of elderly patients with node-positive or high-risk node-negative disease. Results of these trials should provide important information on the range of uses of capecitabine in treating breast cancer.

Original languageEnglish (US)
Pages (from-to)29-32
Number of pages4
JournalOncology (Williston Park, N.Y.)
Volume16
Issue number10 Suppl 12
StatePublished - Oct 2002
Externally publishedYes

Fingerprint

docetaxel
Neoadjuvant Therapy
Breast Neoplasms
Fluorouracil
Epirubicin
Cyclophosphamide
Aptitude
Capecitabine
Paclitaxel
Methotrexate
Reaction Time
Disease Progression
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Current and planned trials with capecitabine in adjuvant/neoadjuvant therapy of breast cancer. / Livingston, Robert B.

In: Oncology (Williston Park, N.Y.), Vol. 16, No. 10 Suppl 12, 10.2002, p. 29-32.

Research output: Contribution to journalArticle

@article{ea586ade0b3247f3bd7f2400db3f5ee0,
title = "Current and planned trials with capecitabine in adjuvant/neoadjuvant therapy of breast cancer.",
abstract = "The demonstration of the activity of capecitabine (Xeloda) in advanced breast cancer and of the ability of capecitabine/docetaxel (Taxotere) to improve tumor response, time to disease progression, and survival in this setting has prompted considerable interest in examining uses of capecitabine in adjuvant and neoadjuvant therapy. Trials are planned to compare capecitabine/docetaxel with docetaxel after AC in the adjuvant and neoadjuvant settings, weekly paclitaxel vs capecitabine/docetaxel followed by fluorouracil (5-FU)/epirubicin (Ellence)/cyclophosphamide and local surgery in both adjuvant and neoadjuvant settings, and AC or cyclophosphamide/methotrexate/5-FU vs single-agent capecitabine in adjuvant therapy of elderly patients with node-positive or high-risk node-negative disease. Results of these trials should provide important information on the range of uses of capecitabine in treating breast cancer.",
author = "Livingston, {Robert B}",
year = "2002",
month = "10",
language = "English (US)",
volume = "16",
pages = "29--32",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "10 Suppl 12",

}

TY - JOUR

T1 - Current and planned trials with capecitabine in adjuvant/neoadjuvant therapy of breast cancer.

AU - Livingston, Robert B

PY - 2002/10

Y1 - 2002/10

N2 - The demonstration of the activity of capecitabine (Xeloda) in advanced breast cancer and of the ability of capecitabine/docetaxel (Taxotere) to improve tumor response, time to disease progression, and survival in this setting has prompted considerable interest in examining uses of capecitabine in adjuvant and neoadjuvant therapy. Trials are planned to compare capecitabine/docetaxel with docetaxel after AC in the adjuvant and neoadjuvant settings, weekly paclitaxel vs capecitabine/docetaxel followed by fluorouracil (5-FU)/epirubicin (Ellence)/cyclophosphamide and local surgery in both adjuvant and neoadjuvant settings, and AC or cyclophosphamide/methotrexate/5-FU vs single-agent capecitabine in adjuvant therapy of elderly patients with node-positive or high-risk node-negative disease. Results of these trials should provide important information on the range of uses of capecitabine in treating breast cancer.

AB - The demonstration of the activity of capecitabine (Xeloda) in advanced breast cancer and of the ability of capecitabine/docetaxel (Taxotere) to improve tumor response, time to disease progression, and survival in this setting has prompted considerable interest in examining uses of capecitabine in adjuvant and neoadjuvant therapy. Trials are planned to compare capecitabine/docetaxel with docetaxel after AC in the adjuvant and neoadjuvant settings, weekly paclitaxel vs capecitabine/docetaxel followed by fluorouracil (5-FU)/epirubicin (Ellence)/cyclophosphamide and local surgery in both adjuvant and neoadjuvant settings, and AC or cyclophosphamide/methotrexate/5-FU vs single-agent capecitabine in adjuvant therapy of elderly patients with node-positive or high-risk node-negative disease. Results of these trials should provide important information on the range of uses of capecitabine in treating breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0036780623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036780623&partnerID=8YFLogxK

M3 - Article

C2 - 12435177

AN - SCOPUS:0036780623

VL - 16

SP - 29

EP - 32

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 10 Suppl 12

ER -